Response Evaluation Criteria in Cancer of the Liver (RECICL)

Kanzo/Acta Hepatologica Japonica

Volumn 51, Issue 5, 2010, Pages 261-266

  Kudo, Masatoshi ^a   Kubo, Shouji ^a   Takayasu, Kenichi ^a   Sakamoto, Michiie ^a   Tanaka, Masatoshi ^a   Ikai, Iwao ^a   Furuse, Junji ^a   Nakamura, Kenji ^a   Makuuchi, Masatoshi ^a  

^a Liver Cancer Study Group of Japan   (Japan)

Author keywords

Hepatocellular carcinoma; Liver Cancer Study Group of Japan; RECIST criteria; Response evaluation criteria; WHO criteria

Indexed keywords

ARTICLE; JAPAN; LIVER CELL CARCINOMA; WORLD HEALTH ORGANIZATION;

EID: 77953550934     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.51.261     Document Type: Article

References (16)

1. WHO handbook for reporting results of cancer treatment, World Health Organization Offset Publication, Geneva (Switzerland), 1979
2. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3): 205-216
3. Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma AJR Am J Roentgenol 2000; 175 (3): 699-704
4. Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002; 95 (9): 1931-1937 (Pubitemid 35222173)
5. Kudo M. Local ablation therapy for hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2004; 39 (3): 205-214 (Pubitemid 38519424)
6. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria Invest New Drugs 1992; 10 (4): 239-253
7. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000; 92 (3): 179-181
8. Llovet JM, Beaugrand M. Hepatocellular carcinoma present status and future prospects. J Hepatol 2003; 38(Suppl 1): S136-149 (Pubitemid 39658641)
9. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100 (10): 698-711
10. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999; 91 (6): 523-528 (Pubitemid 29157060)
11. Park JO, Lee SL Song SY, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003; 33 (10): 533-537
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2): 228-247